Leap Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LPTX research report →
Range $5.5 – $5.5
Price Chart
About the company
Leap Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing treatments for various cancers. At the forefront of its pipeline is DKN-01, a monoclonal antibody designed to block Dickkopf-related protein 1 (DKK1).
- CEO
- Douglas E. Onsi
- IPO
- 2017
- Employees
- 52
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on LPTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $31.86M
- P/E
- 0.82
- Fwd P/E
- 4.53
- PEG
- -0.00
- P/S
- 18.70
- P/B
- 0.68
- EV/EBITDA
- -3.41
- Div Yield
- 0.00%
- Gross Margin
- 78.51%
- Op Margin
- -121.08%
- Net Margin
- 3111.38%
- ROE
- 135.16%
- ROIC
- -1.94%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-36,540,000
- Net Income
- $4.82M+107.1%
- EPS
- $0.07+104.0%
- OCF Growth
- +27.2%
- FCF Growth
- +27.2%
- 52W High
- $3.58
- 52W Low
- $0.22
- 50D MA
- $0.71
- 200D MA
- $0.45
- Beta
- 0.09
- RSI (14)
- 77
- Avg Volume
- 26.09M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Cypherpunk posted its first operating profit as Zcash mining launched, treasury growth accelerated, and management reiterated a long-term plan to scale into a broader privacy technology platform.· November 16, 2026
- First quarter of operating profit: income from operations was $2.6 million.
- Mining launched on August 18 and produced 8,967 ZEC in 44 days at about 95% uptime.
- Zcash treasury swelled to $470.1 million in value at quarter-end, with more than 341,858 ZEC held after October activity.
- The company raised $56.5 million net via ATM and said proceeds are funding fleet expansion, ZEC purchases, and privacy tech investments.
- Management reiterated long-term targets of 25% average network hash rate and at least 5% of circulating ZEC supply.
Reported revenue was $9.9 million from Zcash mining, generated over the 44 days from August 18 through September 30, at an average fair value of about $1,105 per ZEC. Cost of revenue excluding depreciation was $0.9 million, depreciation was $1.2 million, and general and administrative expense was $4.9 million versus $1.9 million in the same quarter last year, with $2.2 million of that increase from stock-based compensation. Income from operations was $2.6 million, a first operating profit for the company. Below operating income, the company recorded a noncash unrealized gain of $330.8 million on its ZEC holdings, leading to net income of $306 million, or $1.44 per basic share and $1.13 per diluted share; it also recorded a $27.5 million tax provision. At September 30, cash and cash equivalents were $56 million, ZEC holdings were valued at $470.1 million, and the company had raised $56.5 million net under its ATM. Forward-looking, management said it intends to use ATM proceeds for additional mining equipment, open-market ZEC purchases, operating expenses, and privacy technology investments; it also said $30 million is reserved for next-generation Bitmain equipment, with delivery expected in mid-2027.
Doug Onsi framed the quarter as a milestone because Cypherpunk launched mining, generated operating profit, and kept adding to the ZEC treasury without selling mined coins. He emphasized disciplined capital allocation, saying the ATM was raised to fund fleet growth, opportunistic ZEC purchases, and future privacy technology investments rather than force sales of mined ZEC. His tone was upbeat but measured, with repeated emphasis on transparency, responsible stewardship, and building a diversified privacy technology company.
Doug Onsi walked through the key financials: $9.9 million of mining revenue, $0.9 million of hosting-related cost of revenue, $1.2 million of depreciation, $4.9 million of G&A, and $2.6 million of operating income. He highlighted the $330.8 million unrealized gain from marking ZEC holdings to market and the resulting $27.5 million tax provision, which produced $306 million of net income. He also said the company ended the quarter with $56 million in cash and cash equivalents, $470.1 million of ZEC holdings, and $56.5 million of net ATM proceeds, which will be used to expand the business without selling mined ZEC.
Analysts focused on how Cypherpunk gets to its 25% network hash-rate target, what the $30 million Bitmain order contributes, and how much more capex would be needed as network hash rate rises. Management said the order was sized to maintain or modestly grow its share as network hash rate expands, but it could not give exact machine specs or pricing yet. Another question centered on how the company decides between buying ZEC, buying mining equipment, and using the ATM; management said the old mNAV framework matters less now that the company has an operating mining business, and that it evaluates both tokens and machines based on relative opportunity and a sum-of-the-parts view. Management also said future privacy investments could include private AI, private communications, wallets, and VPN-related technologies, but gave no specific transactions to announce.
The call showed a company that has already turned its new mining business into operating profit, with strong uptime and low reported mining cost per ZEC. Management also has clear long-term accumulation goals for both ZEC holdings and network share, and says the ATM gives it the capital to keep buying equipment and tokens without becoming a forced seller. They also signaled a broader opportunity set in privacy tech beyond Zcash alone.
The company’s reported earnings were heavily driven by a large noncash unrealized gain on ZEC, so results will swing with the token price in both directions. Management could not provide specific Bitmain machine pricing or a detailed capex roadmap to reach 25% network hash rate, and said those plans depend on future market conditions and network growth. The business also faces execution risk as it expands mining, deploys capital from the ATM, and pursues new privacy technology investments without any guaranteed transactions yet.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 73.4%
- Shares Outstanding
- 41.39M
- Float Shares
- 30.40M
of shares held by institutions
43 13F filers
Buy/sell ratio 15.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 2.13M | ▲ 966.43K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 17, 23 | Martin Patricia A. | other | 0 |
| Jan 17, 23 | Richard Christian M | other | 0 |
| Sep 24, 21 | BeiGene, Ltd. | buy | 2,543,800 |
| Mar 12, 20 | BeiGene, Ltd. | other | 0 |
| Mar 12, 20 | BeiGene, Ltd. | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our LPTX coverage
Recent articles, reports, and earnings notes.
No research on LPTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LPTX report →Leap Therapeutics (NASDAQ:LPTX) vs. Panbela Therapeutics (OTCMKTS:PBLA) Head-To-Head Analysis
defenseworld.net · Mar 3
Leap Therapeutics (NASDAQ:LPTX) and Nemus Bioscience (OTCMKTS:NMUS) Critical Contrast
defenseworld.net · Jan 11
Contrasting Leap Therapeutics (NASDAQ:LPTX) and UCB (OTCMKTS:UCBJF)
defenseworld.net · Dec 31
Reviewing Leap Therapeutics (NASDAQ:LPTX) and Vincerx Pharma (NASDAQ:VINC)
defenseworld.net · Dec 28
Analyzing PaxMedica (NASDAQ:PXMD) and Leap Therapeutics (NASDAQ:LPTX)
defenseworld.net · Dec 18
Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results
prnewswire.com · Nov 12
Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy
prnewswire.com · Nov 12
Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025
prnewswire.com · Oct 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.